If the tweaking offered no advantage, for example, SNY's glulisine, over lispro and aspart, then there wouldn't be a market. If the tweaking offered advantage, like HALO and BIOD's if confirmed in phase III, there would be a market.
Look, the new developments on insulin are very straightforward, either ultra fast acting as meal time insulin like HALO/BIOD's or ultra long acting like NVO's degludec.
Market Data 
Markets 
AI
